SPY328.17-10.05 -2.97%
DIA266.28-8.38 -3.05%
IXIC11,081.16-350.19 -3.06%

Credit Suisse Reiterates Outperform on Mirati Therapeutics, Raises Price Target to $190

Credit Suisse analyst Evan Seigerman reiterates Mirati Therapeutics (NASDAQ:MRTX) with a Outperform and raises the price target from $140 to $190.

· 10/08/2020 07:56
Credit Suisse analyst Evan Seigerman reiterates Mirati Therapeutics (NASDAQ:MRTX) with a Outperform and raises the price target from $140 to $190.